HLA-G Neo-Expression on Tumors

Frontiers in Immunology

卷:11

Maria Loustau²  Raphaelle Dréan²  Julien Caumartin²  Pierre Langlade-Demoyen²  Martin Lecomte³  François Anna⁴ 

[1] CNRS URA 3015, Paris, France;

[2] Invectys, Paris, France;

[3] Molecular Retrovirology Unit, Institut Pasteur, CNRS, UMR 3569, Paris, France;

[4] Molecular Virology and Vaccinology Unit, Virology Department, Institut Pasteur &

关键词: HLA-G;    immune checkpoint;    hematopoietic tumors;    solid tumors;    immunotherapy;   

DOI  :  10.3389/fimmu.2020.01685

来源: DOAJ

【 摘 要 】

HLA-G is known to modulate the immune system activity in tissues where physiological immune-tolerance is necessary (i.e., maternal-fetal interface, thymus, and cornea). However, the frequent neo-expression of HLA-G in many cancer types has been previously and extensively described and is correlated with a bad prognosis. Despite being an MHC class I molecule, HLA-G is highly present in tumor context and shows unique characteristics of tissue restriction of a Tumor Associated Antigen (TAA), and potent immunosuppressive activity of an Immune CheckPoint (ICP). Consequently, HLA-G appears to be an excellent molecular target for immunotherapy. Although the relevance of HLA-G in cancer incidence and development has been proven in numerous tumors, its neo-expression pattern is still difficult to determine. Indeed, the estimation of HLA-G's actual expression in tumor tissue is limited, particularly concerning the presence and percentage of the new non-canonical isoforms, for which detection antibodies are scarce or inexistent. Here, we summarize the current knowledge about HLA-G neo-expression and implication in various tumor types, pointing out the need for the development of new tools to analyze in-depth the HLA-G neo-expression patterns, opening the way for the generation of new monoclonal antibodies and cell-based immunotherapies.

【 授权许可】

Unknown